← All trials
NCT05540288
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Sep 14, 2022
- Last posted
- Sep 14, 2022
- Enrollment
- 266
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of NantesLead sponsor
- University of NantesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.